Log in to your Inderes Free account to see all free content on this page.

OssDsign

10.04

SEK

+0.9 %

OSSD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

4 following

+0.9%

+24.72%

+47.21%

+8.07%

+25.5%

+32.11%

+16.74%

-22.29%

-42.23%

OssDsign operates in the pharmaceutical industry. The company is specialized in the research and development of pharmaceuticals for bone defects. The pharmaceuticals are based on bioceramic material whose composition is used to improve the healing process in various cases of patient injuries. The products are resold as implants and are mainly used for the treatment of head injuries.

Market cap

980.5M SEK

Turnover

3.86M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

4.2.

2025

Annual report '24

ShowingAll content types

Regulatory press release12/18/2024, 10:10 AM

Extraordinary General Meeting held in OssDsign AB

Regulatory press release11/29/2024, 6:00 AM

Notice to attend the extraordinary general meeting in OssDsign AB

Press release11/14/2024, 3:30 PM

Redeye: OssDsign Q3 - Better than expected

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release11/13/2024, 5:19 AM

Carnegie Commissioned Research: OssDsign: Continued strong development – Q3 review

Press release11/12/2024, 7:41 AM

Carnegie Commissioned Research: OssDsign: Continued strong sales momentum – Q3 initial comment

Regulatory press release11/12/2024, 6:00 AM

OssDsign AB (publ) publishes Q3 2024 Interim Report and raises guidance on gross margin

Press release10/8/2024, 3:38 PM

Carnegie Commissioned Research: OssDsign: Solid yet uneventful quarter expected – Q3 preview

Press release10/2/2024, 7:00 AM

OssDsign AB: OssDsign has appointed Stephen Anderson as Vice President of Marketing

Press release8/21/2024, 5:16 AM

Carnegie Commissioned Research: OssDsign: H1(24) in the books, eyes on H2(24) and onwards

Press release8/20/2024, 2:19 PM

Redeye: OssDsign Q2 - Far from fairly priced

Regulatory press release8/20/2024, 5:00 AM

OssDsign AB (publ) publishes Q2 2024 Interim Report

Press release7/11/2024, 4:38 AM

Carnegie Commissioned Research: OssDsign: Closing H1 strongly; hope of even stronger H2 momentum

Regulatory press release6/25/2024, 1:00 PM

Annual General Meeting held in OssDsign AB

Press release6/24/2024, 12:00 PM

OssDsign AB: Withdrawal of proposed incentive programs and revised proposal on board composition and fees ahead of AGM in OssDsign

Regulatory press release6/4/2024, 6:00 AM

OssDsign AB: OssDsign publishes Annual Report 2023

Press release5/30/2024, 10:28 AM

OssDsign AB: 5,000 patients treated with OssDsign Catalyst® in the U.S.

Regulatory press release5/24/2024, 12:22 PM

OssDsign AB: NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB

Regulatory press release5/16/2024, 7:28 AM

OssDsign AB: Change of financial calendar

Press release5/15/2024, 6:16 AM

Redeye: OssDsign Q1 - An accelerating turnaround

Press release5/15/2024, 4:24 AM

Carnegie Commissioned Research: OssDsign: A new beginning – Q1 review

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.